Bayer sells Dr Scholls footcare brand to US firm for USD 585 million
Bayer, whose stock has slumped amid lawsuits over an alleged cancer-causing effect of its Roundup weed killer, struck a deal in May to sell the US sun care brand Coppertone to Nivea maker Beiersdorf for $550 million.
FRANKFURT: Germany's Bayer signed a deal on Monday to sell its Dr Scholl's foot care brand to U.S. private investment firm Yellow Wood Partners for $585 million, the second of two consumer care products it had put on the block.
Bayer, whose stock has slumped amid lawsuits over an alleged cancer-causing effect of its Roundup weed killer, struck a deal in May to sell the US sun care brand Coppertone to Nivea maker Beiersdorf for $550 million.
The divestments are part of a wider overhaul unveiled in November by Bayer Chief Executive Werner Baumann, who is under pressure to boost the share price.
Bayer's Dr Scholl's, which generated $234 million in sales last year, is primarily a North American brand. Rival Reckitt Benckiser owns the Scholl footcare business outside North America.
Bayer acquired weed killer Roundup as part of the $63 billion takeovers of U.S. seeds and pesticides maker Monsanto last year. The German company has said Roundup is safe to use.
The German group, which is scheduled to release second-quarter results on July 30, is also looking for a new owner of its animal health business, the world's largest maker of flea and tick control products for pets, which analysts have said could fetch 6 billion to 7 billion euros.
Reuters this month quoted sources familiar with the matter as saying Bayer had approached U.S. drug firm Elanco Animal Health about a possible tie-up.
Bayer's consumer healthcare business, bolstered by the 2014 acquisition of a Merck & Co division for $14 billion, will focus on remaining brands that require more medical expertise.
The business has faced falling revenues as U.S. consumers switched from established drugstores to online shops.
Boston-based Yellow Wood will create a standalone company for Dr Scholl's consumer brand and it plans to invest in the business to drive growth and profitability, Bayer added.
Read Also: Bayer welcomes call for new trial in $2 billion glyphosate-based weedkiller case
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd